FOLH1 and posterior cortical atrophy: The advent of next-generation imaging (mpMRI, prostate-specific membrane antigen–positron emission tomography (PSMA-PET/TC), genomic profiling, new drugs targeting the androgen receptor axis (Abiraterone, Enzalutamide, Apalutamide), but also molecular alterations in PCa cells (poly(ADP) ribose polymerase enzyme inhibitors) has been driving increasingly precise and patient-tailored treatments.